Baumal Caroline
Chief Medical Officer
Baumal Caroline has filed 5 SEC Form 4 filings (11 transaction rows) across 1 company, with disclosures dating back to 2026. 5 of those filings fall inside the rolling window. Most recent filing: May 14, 2026.
On the most recent filing, Baumal Caroline is listed as Chief Medical Officer at Apellis Pharmaceuticals, Inc. Inside the rolling window, Baumal Caroline reported no open-market purchases and 3 open-market sales totaling $175K in APLS. The largest disclosed transaction in the window is a sale of 3,020 APLS shares on Jan 5, 2026, worth $77K.
Companies traded
Other insiders at APLS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$175K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Baumal Caroline made?
Baumal Caroline has filed 5 SEC Form 4 filings (11 transaction rows) across 1 company since 2026.
Which companies does Baumal Caroline trade?
Baumal Caroline has filed SEC Form 4 disclosures for 1 company, including APLS.
When was Baumal Caroline's most recent SEC Form 4 filing?
Baumal Caroline's most recent SEC Form 4 filing on Tracefour is dated May 14, 2026.
What is Baumal Caroline's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Baumal Caroline is listed as Chief Medical Officer.
What is Baumal Caroline's total buy and sell value in the current window?
Inside the rolling retention window, Baumal Caroline bought $0 and sold $175K based on SEC Form 4 filings.
What was Baumal Caroline's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 3,020 APLS shares on 2026-01-05, worth $77K, per SEC Form 4 filings.